Intermittent fasting (IF) for six months resulted in an average weight reduction of 8% and a 16% decrease in body fat among overweight middle-aged adults.
Significant improvements were observed in lipid profiles, notably an 11% reduction in non-HDL cholesterol and a decrease in plasma triglycerides by up to 23.4%.
Despite significant weight loss, IF did not lead to changes in fasting glucose, insulin sensitivity (HOMA-IR), blood pressure, or carotid intima-media thickness.
Transcriptomic analysis revealed a downregulation of glucagon-like peptide 1 (GLP-1) and related enteroendocrine hormone transcripts in the colon mucosa.
Background: The Intermittent Fasting Paradox
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
